ArticleThe Journal of clinical and aesthetic dermatology2026
Low-Dose Isotretinoin: An Option for the Treatment of Scalp and Facial Rosacea.
Article in The Journal of clinical and aesthetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extrafacial rosacea involving the scalp is an uncommon manifestation of acne rosacea, for which evidence-based treatment guidance is limited. With this retrospective study, we aimed to evaluate the effectiveness and tolerability of low-dose isotretinoin in patients with rosacea involving both the face and scalp. We conducted an observational chart review of adult male patients treated with isotretinoin for this condition at our multisite private practice between 2012 and 2022; 21 patients met inclusion criteria. Treatment courses were short with a low dose (mean cumulative dose: 81.0 mg/kg; mean daily dose: 0.67 mg/kg/day; mean duration: 3.95 months). Complete clinical clearance of facial and scalp disease was achieved in 85.7% of patients, and treatment was well tolerated, with 95.2% of patients completing a full therapeutic course. This study suggests that low-dose, short-duration isotretinoin is a viable and effective systemic treatment option for extrafacial rosacea and may fill an important gap in the management of refractory scalp disease.
Indexed as
Identifiers
42239842PMC13229152What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.